Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.aartipharmalabs.com | |
Market Cap | 4,228.61 Cr. | |
Enterprise Value(EV) | 4,424.67 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 21.35 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | 21.85 | Trailing Twelve Months Ending 2023-03 |
Industry PE | 38.54 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 182.90 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 2.55 | Calculated using Price: 466.60 |
Dividend Yield | 0.43 | Period Ending 2023-03 |
No. of Shares Subscribed | 9.06 Cr. | 90,626,008 Shares |
FaceValue | 5 | |
About Aarti Pharmalabs Ltd. | ||
The company is an, internationally recognised manufacturer of Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, New Chemical Entities (NCE), and xanthine derivatives situated in India. In order to build a sustainable future, it integrates process chemistry proficiency (recipe focus) with scale-up engineering proficiency (asset utilisation). |
1 Day |
|
-1.00% |
1 Week |
|
+13.80% |
1 Month |
|
+12.50% |
3 Month |
|
+4.60% |
6 Month |
|
+20.30% |
1 Year |
|
|
2 Year |
|
|
5 Year |
|
|
10 Year |
|
3 years | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -2.02 | 18.23 | 13.35 | |
Return on Capital Employed (%) | -1.87 | 19.40 | 16.11 | |
Return on Assets (%) | -1.84 | 11.98 | 9.06 |
Particulars | 4 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 0 | 1,386 | 1,558 | 1,658 | |
Non Curr. Liab. | 73 | 81 | 97 | ||
Curr. Liab. | 0 | 581 | 592 | 559 | |
Minority Int. | |||||
Equity & Liab. | 0 | 2,040 | 2,231 | 2,313 | |
Non Curr. Assets | 1,012 | 1,075 | 1,147 | ||
Curr. Assets | 0 | 1,028 | 1,156 | 1,167 | |
Misc. Exp. not W/O | |||||
Total Assets | 0 | 2,040 | 2,231 | 2,313 |
Particulars | 3 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Net Sales | 1,200 | 1,945 | ||
Other Income | 4 | 2 | ||
Total Income | 1,204 | 1,948 | ||
Total Expenditure | -995 | -1,603 | ||
PBIDT | 209 | 344 | ||
Interest | -12 | -21 | ||
Depreciation | -42 | -63 | ||
Taxation | -33 | -67 | ||
Exceptional Items | ||||
PAT | 122 | 193 | ||
Minority Interest | ||||
Share Associate | ||||
Other Related Items | ||||
Consolidated Net Profit | 122 | 193 | ||
Adjusted EPS | 0 | 4,890 | 21 |
Particulars | 3 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | -44 | 263 | ||
Cash Fr. Inv. | -139 | -158 | ||
Cash Fr. Finan. | 260 | -163 | ||
Net Change | 78 | -58 | ||
Cash & Cash Eqvt | 0 | 83 | 25 |
Mon, 13 Nov 2023
Announcement under Regulation 30 (LODR)-Earnings Call Transcript Transcript of Earnings Conference Call for Q2 FY24 Financial Results held on November 9 2023 |
Thu, 09 Nov 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Publication of Audited Financial Results for Quarter and Half year ended September 30 2023 |
Thu, 09 Nov 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Audio recording of Earnings Conference Call of Financial Results for Q2/ H1 FY24 |
Fri, 08 Dec 2023 |
|
|
|
|
|